The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 11, 2018

Filed:

Mar. 12, 2013
Applicant:

Hanmi Science Co., Ltd, Gyeonggi-do, KR;

Inventors:

Young Min Kim, Yongin-si, KR;

Dae Jin Kim, Seoul, KR;

Sung Min Bae, Seoul, KR;

Chang Ki Lim, Suwon-si, KR;

Se Chang Kwon, Seoul, KR;

Gwan Sun Lee, Seoul, KR;

Assignee:

HANMI SCIENCE CO., LTD., Hwaseong-si, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); C07K 1/107 (2006.01); A61K 47/48 (2006.01); C07K 19/00 (2006.01); C07K 14/505 (2006.01); C07K 14/535 (2006.01); C07K 14/56 (2006.01); C07K 14/61 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
A61K 47/48369 (2013.01); A61K 47/68 (2017.08); A61K 47/6811 (2017.08); A61K 47/6813 (2017.08); A61K 47/6835 (2017.08); C07K 14/505 (2013.01); C07K 14/535 (2013.01); C07K 14/56 (2013.01); C07K 14/61 (2013.01); C07K 16/46 (2013.01); C07K 19/00 (2013.01); C07K 2317/52 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2319/30 (2013.01);
Abstract

Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.


Find Patent Forward Citations

Loading…